"Eflornithine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
| Descriptor ID |
D000518
|
| MeSH Number(s) |
D12.125.068.665.340 D12.125.095.765.340
|
| Concept/Terms |
Eflornithine- Eflornithine
- alpha-Difluoromethyl Ornithine
- Ornithine, alpha-Difluoromethyl
- alpha Difluoromethyl Ornithine
- alpha-Difluoromethylornithine
- alpha Difluoromethylornithine
Eflornithine Hydrochloride- Eflornithine Hydrochloride
- Hydrochloride, Eflornithine
- Eflornithine Monohydrochloride, Monohydrate
- Monohydrochloride, Monohydrate Eflornithine
|
Below are MeSH descriptors whose meaning is more general than "Eflornithine".
Below are MeSH descriptors whose meaning is more specific than "Eflornithine".
This graph shows the total number of publications written about "Eflornithine" by people in this website by year, and whether "Eflornithine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Eflornithine" by people in Profiles.
-
Improvement of dermatological symptoms in patients with Bachmann-Bupp syndrome using difluoromethylornithine treatment. Pediatr Dermatol. 2023 May-Jun; 40(3):528-531.
-
Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial. Dis Colon Rectum. 2022 Apr 01; 65(4):536-545.
-
Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. N Engl J Med. 2020 09 10; 383(11):1028-1039.
-
Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients. Int J Cancer. 2020 12 15; 147(12):3550-3559.
-
Clinical importance of eflornithine (a-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol. 2018 04; 7(2):CNS16.
-
Chemoprevention of familial adenomatous polyposis. Fam Cancer. 2016 07; 15(3):467-75.
-
An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016 Feb; 65(2):286-95.
-
Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci. 2014 Sep; 1325:108-26.
-
Polyamine inhibitors for treatment of feline oral squamous cell carcinoma: a proof-of-concept study. J Vet Dent. 2013; 30(3):140-5.
-
Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia. Cancer Prev Res (Phila). 2011 Jun; 4(6):829-39.